12-Debenzoylpaclitaxel | 186799-63-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 12-Debenzoylpaclitaxel
• 英文别名: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-1,2,9-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-15-yl] (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoate
• CAS: 186799-63-3
• 化学式: C₄₀H₄₇NO₁₃
• 分子量: 749.8
• InChiKey: UBFOEBYDKFYZED-KWIOUIIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  54
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  215
• 氢给体数：
  5
• 氢受体数：
  13

文献信息

• Acid-labile lipophilic prodrugs of chemo-therapeutic anti-cancer agents
  申请人：Veiled Therapeutics LLC

  公开号：EP2717699B1

  公开（公告）日：2020-06-03
• MEDICAL DEVICE COATINGS FOR RELEASING A THERAPEUTIC AGENT AT MULTIPLE RATES
  申请人：Moore William F.

  公开号：US20080195079A1

  公开（公告）日：2008-08-14

  Medical device coatings are provided that simultaneously release a therapeutic agent at different rates from different portions of the medical device coating. In a first embodiment, medical device coatings are provided that include particles comprising a therapeutic agent with two or more different particles sizes within a single layer on a surface of the implantable device. In a second embodiment, medical device coatings are provided having a higher concentration of the therapeutic agent in a first region of the coating than in a second region of the coating. In a third embodiment, medical device coatings are provided that are formed by certain coating processes wherein the droplet size of a spray coating solution is changed during the coating process. These coating processes preferably include applying a solution comprising a therapeutic agent and a suitable solvent to a surface of an implantable medical device. In a fourth embodiment, methods of treatment are provided that include implanting a coated medical device.
• Combination cancer therapy with bis(thiohydrazide) amide compounds
  申请人：Dahl Thomas A

  公开号：US20090137682A1

  公开（公告）日：2009-05-28

  A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g., Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R 1 -R 4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R 7 -R 8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.
• US8017654B2
  申请人：——

  公开号：US8017654B2

  公开（公告）日：2011-09-13